BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 30, 2018--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that it will
report its third quarter 2018 financial and operating results on
Thursday, November 8th, 2018, following the close of the U.S.
financial markets. BioTime management will also host a conference call
and webcast on Thursday, November 8th, 2018, at 4:30 p.m.
Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2018
financial results and to provide a business update.
Interested parties may access the conference call by dialing (866)
888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere
outside the U.S. and should request the “BioTime Inc. Call”. A live
webcast of the conference call will be available online in the Investors
section of BioTime’s website. A replay of the webcast will be available
on BioTime’s website for 30 days and a telephone replay will be
available through November 15th, 2018, by dialing (855)
859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere
outside the U.S. and entering conference ID number 8658619.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE American: OCX), and a
private company, AgeX Therapeutics, Inc.
Regarding the dividend distribution of AgeX Therapeutics, Inc. that we
have previously announced, and with respect to certain index funds in
Israel, we have been informed that a third party has committed to
purchase any and all shares of AgeX from all index funds in Israel at a
price of $2.80 per share and up to a maximum dollar amount of $2.5
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005287/en/
Source: BioTime, Inc.
BioTime Inc. IR
Ioana C. Hone, 510-871-4188
Gitanjali Jain Ogawa, 646-378-2949